![](https://library.celltelligence.com/wp-content/uploads/2024/02/Screenshot-2024-02-06-at-18.54.11.png)
$0
Thoughts on Regeneron Acquiring 2seventy bio’s Pipeline; How Could Regeneron Leverage its New Cell Therapy Pipeline?
On Tuesday, January 30, Regeneron announced (press release) the formation of Regeneron Cell Medicines based on an asset purchase agreement to acquire full development and commercialization rights to 2seventy bio’s pipeline, along with the clinical manufacturing capabilities, and related platform technologies.